Join our daily newsletter At The Bell to receive exclusive market insights
- Life science company Cellmid (CDY) has received a notice of intention from the Chinese Patent Office for its evolis brand
- This is a key milestone for the company’s strategy of protecting and establishing evolis in China
- Evolis is Cellmid’s range of anti-aging hair care and hair loss products
- In mid-morning trade Cellmid’s share price is down a slight 2.50 per cent with shares trading for 19.5 cents apiece
Life science company Cellmid (CDY) has received a notice of intention from the Chinese Patent Office for its evolis brand.
The application titled “Method of Treatment of Alopecia with Monoterpenoids” will expire in December 2034.
The Chinese patent will provide protection in the territory for hair therapy formulations which include small molecules called monoterpenoids that are originally derived from botanical extracts.
Granting of this patent in China is an important commercial milestone for Cellmid’s Chinese product strategy.
It provides a broad protection of the FGF5 technology and several ingredients, adding value to the company’s portfolio.
The method covered by the patent involves the administration of skin cream that controls the regulatory protein and hair growth factor 5 (FGF5).
Detailed scientific studies have shown that FGF5 activity in hair follicles is associated with the disruption of the hair cycle, leading to the withdrawal from the growth or anagen phase and the entry into the regressive catagen phase, followed by hair loss.
Meticulous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Tokyo showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the antigen phase.
With improved protection at formulation and brand level, the patent adds to the product security along with the YPB consumer protection technology, the licensed “Australian Made” logo, and the registered evolis trademarks.
The grant of the Chinese patent comes at a key time in the expansion of Cellmid’s distribution into China following the announcement of the Cross Border e-commerce partnership with Aeon International. It also follows the agreement with Fukangren to register products with the SFDA and sell the products in Chinese Pharmacies and clinics.
In mid-morning trade Cellmid’s share price is down a slight 2.50 per cent with shares trading for 19.5 cents apiece.
